Kantar Health Blog

  • Quality vs. Quantity in Melanoma

    by Stephanie Hawthorne | Oct 2, 2012
    Stephanie Hawthorne
    GSK is looking to challenge Zelboraf (vemurafenib), Roche’s BRAF inhibitor, with its own BRAF targeting molecule, dabrafenib. In addition to BRAF, GSK is looking to make an impact in melanoma with its first-in-class MEK inhibitor, trametinib. ESMO 2012
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    As Sutent is extremely well entrenched as the leader in this setting, it is difficult to believe that the COMPARZ trial, which demonstrated non-inferiority of Votrient results rather than superiority, will have much impact. ESMO 2012
    Continue Reading > | Go comment! | Share
  • The Belle of the Ball: PD-1 as a Hot New Target

    by User Not Found | Jun 5, 2012
    User Not Found
    These studies demonstrate the potential of targeting the PD-1/PD-L1 checkpoint as a therapeutic strategy. These molecules appear to be very well tolerated and have efficacy in many advanced tumor types. Many questions remain unanswered about this novel approach to targeting cancer including: is efficacy limited to tumors that express PD-L1? ASCO 2012
    Continue Reading > | Go comment! | Share
  • User Not Found
    It is likely that dabrafenib and trametinib will receive regulatory approval though GSK has yet to file. With a somewhat better safety profile than Zelboraf, it will be a worthy competitor in the melanoma market and provide a treatment alternative for patients with BRAF mutations. Preliminary data from the combination of dabrafenib and trametinib looks very impressive in terms of safety and efficacy and may ultimately prove superior. ASCO 2012
    Continue Reading > | Go comment! | Share
  • User Not Found
    With the positive data, cabozantinib will clearly represent a new treatment option for MTC patients when it gets approved. But how will it be used by physicians? Will it compete with Caprelsa which earned its MTC regulatory approval in the U.S. in 2011 based on the results of ZETA Phase III trial, or will it be used after patients progress on Caprelsa? ASCO 2012
    Continue Reading > | Go comment! | Share